RIC8A and cancer: Blunting the abundance of client oncoproteins through inhibition of the chaperones that fold them is an active strategy in cancer therapeutic development, with Hsp90 inhibitors providing a prominent precedent.43, 44 Blocking the highly specialized chaperones Ric-8A or B, that to date are known to only fold subsets of G protein α subunits, represents an untested target against onco-G-protein-driven cancers.